The researchers demonstrated that the embryonic stem cell therapy significantly reduced MS disease severity in animal models, and offered better treatment results than stem cells derived from human adult bone marrow.
The study was led by
"The cutting-edge work by ImStem, our first spinoff company, demonstrates the success of
The research was supported by a
The cutting-edge work by ImStem ... demonstrates the success of
The researchers compared eight lines of adult bone marrow stem cells to four lines of human embryonic stem cells. All of the bone marrow-related stem cells expressed high levels of a protein molecule called a cytokine that stimulates autoimmunity and can worsen the disease. All of the human embryonic stem cell-related lines expressed little of the inflammatory cytokine.
Another advantage of human embryonic stem cells is that they can be propagated indefinitely in lab cultures and provide an unlimited source of high quality mesenchymal stem cells - the kind of stem cell needed for treatment of MS, the researchers say. This ability to reliably grow high quality mesenchymal stem cells from embryonic stem cells represents an advantage over adult bone marrow stem cells, which must be obtained from a limited supply of healthy donors and are of more variable quality.
"Groundbreaking research like this furthering opportunities for technology ventures demonstrates how the University acts as an economic engine for the state and regional economy," says
The findings also offer potential therapy for other autoimmune diseases such as inflammatory bowel disease, rheumatoid arthritis, and type-1 diabetes, according to Xu, a corresponding author on the study and one of the few scientists in the world to have generated new human embryonic stem cell lines.
There is no cure for MS, a chronic neuroinflammatory disease in which the body's immune system eats away at the protective sheath called myelin that covers the nerves. Damage to myelin interferes with communication between the brain, spinal cord, and other areas of the body. Current MS treatments only offer pain relief, and slow the progression of the disease by suppressing inflammation.
"The beauty of this new type of mesenchymal stem cells is their remarkable higher efficacy in the MS model," says Wang, chief technology officer of ImStem.
The group's findings appear in the current online edition of Stem Cell Reports, the official journal of the
Most Popular Stories
- McDonald's Packages Coffee for National Distribution
- Apple Stock Bounces Back Big Time
- Castro-Blanco Joins Fifth Street Finance Board
- Google Kid Accounts Plan Raises Worries
- Target Slashes Annual Profit Outlook
- Ballmer Steps Down From Microsoft Board
- Honda's Safe Approach Pays Off in Sales
- Islamic Militant in James Foley Beheading Video May Be English
- HTC Makes Windows Version of Flagship One Phone
- GE Healthcare Bringing Jobs to Massachusetts